-
-
-
-
-
-
-
Allakos Announces Positive Phase 2 Results for AK002 in Patients with Xolair Refractory Chronic Spontaneous Urticaria and Provides Additional Data from Chronic Urticaria Study Cohorts
-
-
-
-
-
-
-
Allakos (ALLK) Presents Data from its Eosinophilic Gastrointestinal Diseases Program at ACG
-
-
64,524 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

